|
|
|
|
|
by mentalgear
122 days ago
|
|
Spot on, and beyond the 'double-dipping' business model of "academic publishers" like Elsevier and Springer, there’s a massive systemic issue: taxpayers fund >90% of foundational research, only for private pharma/bio/tech firms to add a thin layer of additional research (or design) on top and then lock it behind patents for decades. Another example of how private interests are offloading the risk and costs to taxpayers while privatizing all the rewards. |
|
Citation needed.
Go to market cost billions and takes a decade. Doesn't sound like a thin layer. I'm not disputing fundamental research in academia is an essential fuel to keep innovation engines running. But the contributions of biotech is not "thin".